Celldex Therapeutics (CLDX)
(Real Time Quote from BATS)
$40.93 USD
-0.23 (-0.56%)
Updated Sep 20, 2024 01:49 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLDX 40.93 -0.23(-0.56%)
Will CLDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Acadia Healthcare (ACHC) Beats Q2 Earnings and Revenue Estimates
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Other News for CLDX
Celldex (CLDX) Receives a Buy from Cantor Fitzgerald
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
Celldex Therapeutics to Present at Upcoming Investor Conferences
Notable Wednesday Option Activity: CLDX, DJT, BOX
Bullish Two Hundred Day Moving Average Cross - CLDX